Our American Cannabis MSO Portfolio Below is the w/e Sept. 13th performance of the 7 largest American multi-state operators, and MTD, in descending order, and their market capitalizations: (Listen to "Money, Money, Money - It's a Rich Man's World!" courtesy of MunAiMarkets) Trulieve Cannabis (TCNNF): UP 13.5% w/e Sept. 13th; UP...
A Comparison of the Returns Of Our 12 Portfolios w/e Sept. 6th
Below are how our 12 portfolios performed w/e Sept. 6th, in descending order, with links to my articles this week on each portfolio where available: American Cannabis MSO Stocks Portfolio; UP 3.6% Conservative "Cannabis" Stocks Portfolio: UP 2.6% Cloud Computing SaaS Stocks Portfolio: DOWN 3.1% (Source) AI Mega-Cap Stocks Portfolio:...
Our Canadian Cannabis LP Portfolio Continued DOWN w/e Sept. 6th
An Introduction The Canadian Cannabis LP Portfolio continues to reel from the August 26th announcement by the Drug Enforcement Administration (DEA) that it had scheduled an administrative hearing for December 2nd to consider differing expert opinions on the Justice Department’s proposal that cannabis be re-classified to that of a Schedule...
Our Conservative “Cannabis” Stocks Portfolio Was UP In August
If you would like to make an investment in the cannabis sector but are wary of the volatility it exhibits then consider the 5 tobacco, beer, and distiller/vintner companies that have major investments in the cannabis sector. Their stock performances are steady week after week - and month after month...
Our American Cannabis MSO Portfolio was DOWN 16% In August
An Introduction Last Monday, August 26th, the Drug Enforcement Administration (DEA) announced that it had scheduled an administrative hearing for December 2nd to consider differing expert opinions on the Justice Department’s proposal that cannabis be re-classified to that of a Schedule III drug under the Controlled Substances Act (CSA)....
Our Canadian Cannabis LP Portfolio Was DOWN 14% In August
An Introduction On August 26th, the Drug Enforcement Administration (DEA) announced that it had scheduled an administrative hearing for December 2nd to consider differing expert opinions on the Justice Department’s proposal that cannabis be re-classified to that of a Schedule III drug under the Controlled Substances Act (CSA). That...